Pharmaresearch, led by CEO Son Ji-hoon, announced on the 13th the successful completion of a roadshow aimed at launching its Polynucleotide (PN)-based skin booster, Rejuran, across five key markets in Western Europe, including the Benelux countries (Belgium, Netherlands, Luxembourg), the UK, and Switzerland.

This initiative was strategically timed with Rejuran's market entry, allowing local medical professionals to gain insights into the unique advantages and clinical applications of the DOT® PN technology. The initial reception, marked by high interest and inquiries from local practitioners, signals significant potential for market penetration and brand acceptance.

The roadshow commenced on the 22nd and 23rd at the Benelux countries, followed by events on the 28th in the UK and the 30th in Switzerland. Notably, the event in the Benelux was hosted in a border area to facilitate access for medical professionals from both Belgium and the Netherlands. The UK event attracted over 250 attendees, showcasing robust engagement from the medical community.

At the symposium, global key opinion leaders shared clinical results and treatment protocols. Strategies for utilizing the Rejuran line, which includes offerings suitable for various applications—such as Rejuran for overall facial rejuvenation, Rejuran I for delicate areas around the eyes, and Rejuran S for wrinkle and scar improvement—were discussed, enhancing the understanding of the product range.

This roadshow extends beyond mere brand introduction; it lays the groundwork for expanding Rejuran's market demand within Europe. Starting in January, Pharmaresearch began its initial shipments to Europe and is developing local distribution networks. Building on the positive feedback received so far, the company is poised to enhance its supply chain and academic marketing efforts.

Following this initial phase in five Western European countries, additional roadshows are slated for Italy in May, Poland in June, and France in September, with plans to extend into Germany and other regions later this year. This forward momentum is critical to establishing a comprehensive brand footprint across Europe.

VIVACY, Pharmaresearch's local partner, remarked that despite being in the initial launch phase, Rejuran has generated considerable inquiries from local practitioners regarding product characteristics and potential applications. This response indicates that the brand's established reputation and trust within the Asian market positively influence its entry into Europe, highlighting Rejuran as a new option for PN skin boosters.

Pharmaresearch emphasizes the necessity of proactively establishing a firm market position in Europe, recognizing it as an emerging market for PN-based injectables. The company asserts that Rejuran, backed by DOT® PN technology and a solid product lineup, is absorbing into the market faster than initially anticipated, prompting an upward revision of internal performance targets.

In conclusion, with the convergence of brand strength and clinical-led communications benefiting market establishment both domestically and abroad, Pharmaresearch plans to bolster its distribution network and academic initiatives to solidify its standing in the European market.